Linrodostat

Linrodostat
Clinical data
Other names	BMS-986205; ONO 7701
Routes of; administration	Oral
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2R)-N-(4-Chlorophenyl)-2-[(1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide;
CAS Number	1923833-60-6;
DrugBank	DB14986;
ChemSpider	58828674;
UNII	0A7729F42K;
Chemical and physical data
Formula	C24H24ClFN2O
Molar mass	410.92 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC1=CC=2C(=CC=NC2C=C1)[C@@H]3CC[C@]([C@H](C(NC4=CC=C(Cl)C=C4)=O)C)(CC3)[H];
	InChI InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16-,17+/m1/s1; Key:KRTIYQIPSAGSBP-ZACQAIPSSA-N;

Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.^[1]

References

Fraunhoffer KJ, Delmonte AJ, Beutner GL, Bultman MS, Camacho K, Cohen B, et al. (2019). "Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor". Organic Process Research & Development. 23 (11): 2482–2498. doi:10.1021/acs.oprd.9b00359. S2CID 208690975.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Clinical data

Other names	BMS-986205; ONO 7701
Routes of administration	Oral
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2R)-N-(4-Chlorophenyl)-2-[(1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
CAS Number	1923833-60-6
DrugBank	DB14986
ChemSpider	58828674
UNII	0A7729F42K
Chemical and physical data
Formula	C₂₄H₂₄ClFN₂O
Molar mass	410.92 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES FC1=CC=2C(=CC=NC2C=C1)[C@@H]3CC[C@]([C@H](C(NC4=CC=C(Cl)C=C4)=O)C)(CC3)[H]
InChI InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16-,17+/m1/s1 Key:KRTIYQIPSAGSBP-ZACQAIPSSA-N